24/12 2010 FRI 13:15
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`~082/099
`
`Pharmacology of CS-747 (Prasugrel,
`LY640315), a Novel, Potent Antiplatelet
`Agent with in Vivo P2Y12 Receptor
`Antagonist Activity
`
`Yoichi Niitsu. Ph.D..' Jose~h A. Jakubowski. Ph.D..3
`Atsuhiro Sugidachi. Ph.D.. and Fumitoshi Asai. Ph.D.1
`
`,2
`
`ABSTRACT
`.._-_._._._. __ .._---_ ..._-_ .._--_._---
`---------------------------------------_._._-----_._.---_._
`class of oral
`is a member of the rhicnopyridinc
`CS-747
`(prasllgrcl. LY6tl031S)
`inhibitors
`that
`riclopidine
`and clopidogrcl, A single orul
`aggregation
`includes
`platelet
`,)1"pl:H<.,kl: "gp\'l:i:tt"i,)n
`administration
`ofCSM74'1 produced
`a dose-related
`inllibi\i,.lIl
`il) !':t1".~
`INao .~pPI'{I)(i1))'IH,ly 10-
`100-{c)kl more
`that
`.!nd
`poreur
`than
`ihar
`o( dopidogl'd
`',lnd
`lid"pidin",
`!''''p(;ctivcly.
`The
`:tnliagt;l't:g'llOI,),
`d'f'CCl o( CS-747 was evident
`at ]0 minutes
`and lasted until 72 hours
`after dosing.
`indicating
`fasr onset
`and long duration
`of action,
`CS-747
`showed more
`potenl'
`anrirhromboric
`activit}'
`compared
`with
`clopidogrci
`ilnd
`ticlopidinc with the same rank order
`as rhc anliaggregawry
`potencies, Combined
`admin
`or hOII!
`of CS"'!47 with aspirin
`istrarion
`to rats produced
`~\lb~l"a!\tiHH)' gre ..rcr i.Ili>ibilion
`platelet
`agg1'l'garlllr\
`and
`thrombus
`Iormation
`t:()J))pa"l~d with
`I::!ch
`:1!~l~IlI alouc.
`'l'hl~
`or CS-747
`antiplnrclcr
`:winIl
`is due
`to irreversible
`and selective) blockade
`of platelet
`P2Y 1), adenosine
`(ADP) recl':ptors by irs active metabolite
`diphosphate
`R-:IJS727,
`In phase
`(:10 and 7S m)!;) produced>
`I studies,
`a single oral dose ofCS-747
`50% inhibition
`ofADl)w
`(:> 48 11()\I)',) ol
`platelet
`induced
`am:\rC/~ati()n. with rapid onset
`(1 hour)
`and long dunuion
`o:' 10 1111:; CS-747
`ilu·io!)_
`111 1,,;•.Ith), v(lhllm'.I."'~,
`'.lnl'l,-(hily
`'H.llYlinl,l1·:ll"i(l!l
`1(,1' 10 day"
`Irom 2 days :If'l.l!l' the firHt
`shower] sig;nilt'~'<Inr cUJ)\lllalive
`()( platelel' 'lggmgaliol\
`inhibiril)1\
`dose until nrlensi 2 cby" 'lflCI'
`the Iinnl dose, Studies
`conducted
`1"0 date
`indicate
`that CS-
`7117 is a highly effective
`antiplareler
`and anrithromboric
`agent
`and is anticipated
`to be
`effective
`in the treatment
`of athcrorhrornbotic
`and other
`ischemic
`vascular
`diseases,
`
`I(EVWORDS: CS,,'7<1],prusuorel, LYBIW315, fl,1387?'J,
`r-199221J, pintelnt (lll9ICI)Dti{)ll,
`antiplattllc)(,
`antithrornhotic, P2Y I ~ receptor
`(-lntiJ\)ol1i~;1.,ADP
`
`Objectives:
`thl< f(·!:.ldC·!f!;llI)llld b(.;abhllf'
`;lflicl(~,
`011 CIJI)\I.lllllil\1I ()lll\i!;
`1.)I:l(W(·~1·2nCS-Jt17 find
`()lopieloHtl:1l.
`!lilln
`COI)'PjJfiJllVl-l
`rl'l.JSM);, ~cc":'dilf.'d by Ih,:,1\<.:<.:r(:,(iiWli(mCOI.ln"';l for C'lrltinllinn M':'<:ii(:;:III·::dl.IC'lIi()n
`ll.lft~;t)niv(:!f!;ity
`;:>(;h(IOI01 Medidne
`Acc,edltatlon:
`to provide eOl"\linuinq'w'clic,ll education tor phvstctans.
`
`(:1.)
`
`li!;l
`
`("1) d<-!:;cribll tll(·~phHllfl:l(;()IIl()y
`
`,Ind Iwlcti(JII!; of CS·o;'t/
`
`:11\1]
`
`The PI;\tdt~~' Pi Rt~t:qHI)f~~ Bk)L'heml!irry, Phy~;')\')gy,Ph:'ftn~\(~d,}~~)',;\I}(l Clir)il:;ll A!'tPI~I~I~~I,:d:()(
`ill Chid', J,:IH:t'lI;tfd F.1'I1;1II\IIII:n,
`(;IIC~;I
`f\,1.iJ.;
`(;1l("1".'i", M ,I)" 1'1>,)) .. HIl(! Marco Cntranco, M.n,
`S,'lIIill,II)'
`ill n'I"MII/)Q.<i.<
`and 111'/1/(,.(/lI.<i.<,volume 31. IHIIl1her 2. ;lOOS, I\ddr('~,
`I<:(lil"or:;,Chri~liH"
`feqlt(~~b: FUII\jIt'J~hi A~al, Ph.n'J Plrilfn)it\~()I()g}'
`l~)( correspondence
`t.~o., I ,Id.,
`r\'1IJh:l~lI1af Biology 1{1:~C:jlrl~hl.i\hi)I';\lIH'il:~,
`'1-
`i)lld l'l~Pfilll'
`illlt!
`:-)imi{ytl
`2-·58 Hiromachi,
`Shill;l!_\i'Wi,··I"" Tokyo
`J")'ill ...
`r'>",,,il;
`t')i"iM~'iH1k)'(),('I,.ip,
`'Ph!lrn·li)("1."W and
`Bj,)i.>I.IY i{"'(i;"·.,r,
`!\1"lc"llb,.
`l4(J-8iJO,
`I,!<.I"'I'<>ky<.',,1<'lIi'I1; 'Oin'("«)r;
`J ,at.""·I1I<..ri",;, Si,"ky',
`(;').,
`J\"~('.:Ir(:h,
`lind C<HlIl'HIl)"
`lndinnu,
`'Bi<.d'edlJ1<.>i<)I!:)'
`i)i:;c,)very
`I-:li
`J ,illy
`J!ldi:'II~II',-,Ji:;,
`'1'1:1, <·IULl) SH4·A(,(,;L O()'J-I..
`C,,),yrigln
`b)' Thieme M"dic,,1 Puhlishcr«,
`1,,,,.,
`:lTl Seventh AV"J\l":, New V,),'It, NY WOOl, USA.
`«;)
`200.)
`I,02, '18(1,l<)",lh,,,,,;.~ht)l
`fl<16,.
`(,17('.1';2005)
`
`184
`
`:01. This page 82 of 99 was completed at 24.12.2010 14:13:35
`Duration: 24.12.2010 13:40:37 - 24.12.201014:21
`Received at the EPO on Dec 24, 2010 14:21 :01. Page 82 of 99
`
`
`IPR2015-01492
`Panacea Biotec Ltd.
`
`
`
`
`Ex. 1044, p. 1 of 11
`
`

`

`24/12
`
`2010 FRI 13:15
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`~083/099
`
`Credit: TUSM do:;iqni,lIC1:; Ihi:, 1,)dl.ll)i,llionaj iJClivily Ior u maximum of 1 CiltW10IY 'j 1;1~lIjitIOWi:l!d the AMA l)hy~;iCii)l1~;H,"(;l)ljnitlon J\Willlj.
`tl1(1thl~hhe
`activitv,
`F,:",11 pily,;k:i(Hl
`l;I1()\,ld cliJil'll ,lilly 111o,:,,,,(:",dit,
`i1ewi;llly spent
`ill Ihe _,dl'Cilliolli,j
`
`PHARMACOLOGY
`
`OF CS-'147/NIII!;U
`
`1"1111.
`
`1B5
`
`aggrega-
`platelet
`including
`activation,
`l~latclet
`of acute
`plays a crucial
`role in the pathogenesis
`tion,
`accidents,
`co]'()n:uy
`syndromes
`and
`cerebrovascular
`Ahhough
`arc acrivared by a variety O! cndo-
`platelets
`W,"1(11I5 :lWllli~I'''', ADP
`\h~: <,'arli<"~I' dCij('.I'ih<"d
`:uld
`w;(~
`is one of
`the most
`importunr
`ag;onisf's
`(or plareler
`activation,
`l,1 l n additioll
`to illduci;lg
`primary
`platelet'
`aggregation,
`ADP released from activated
`platelets
`can
`induce secondary platelet
`aggrq2;ation via the feedback
`process, ampii()'illj.!; and propagating
`platelet
`actlvati.on
`l11du(:(:d hy otlll:!'
`,lW)lIi~I~, AD»
`;~~:IIval\~splalc:kt$
`via
`le:-t:->[ rwo distinct C
`A 1)]' 1\~\:\~pt())'~,;lnd
`lhcl\~ are
`Itt
`PI'()t\~ln-ro\lplt=d AI)!.' I'Ct:epIOI'S, Cq-linkcd
`recep-
`P2Yl
`tors and Gi-linked
`r(.~ccpl'Or~,:H
`P2Yll
`importance of P2Yl2 receptors ill the purho-
`The
`f!;cllesi,s of arterial
`thrombosis
`i~ ,UPI,I\ll'\,<.;d by a series or
`il'lhlbil'I»)'S or thil:'Jl(lpyl'ldllH~
`in VIVO P2YI).
`reports
`that
`(ki'iv',1\'iv(;$,
`tidl)pldllll~(i
`and dnpidng;rcl/
`nrc cf'fcC.1'ive in
`I't;d.,l(,:ing; rhc
`"isk 1)( :Irh(:msd(lrol'ic:'
`V~ISCld:u' disc:1se,7'-',)
`r"low(;vt~l',
`rhesc
`:Igerll's are hy no means
`S:lI'i:;f~ICtOJ'y in
`terms
`of
`adverse
`cffocrs
`and
`anriplarclcr
`efficacy, At
`commonly
`used doses,
`riclopidinc may cause agranulo--
`cyrosis II)
`and
`thrombotic
`thrombocytopenic
`purpura
`(TTP)
`,11,12 In addition,
`the use of riclopidinc
`is dis-
`in patients with renal or hcpuric dY$f\IlKti<)Il,C;,')
`couraged
`Clopidogrcl
`has been
`dcmonstrutcd
`It) b<~ $}\f~~l' rhun
`ir
`riclopidinc,
`also cause
`'ITP,I:l,lo1
`:\Jl-hOllgh
`l)fIY
`have c,;\llsed
`concern rc,gardil1R
`H(1Wt'V'~I',
`t'(;l:\~lIl, slildit~s
`"I
`id
`I
`'
`'" I~J(,
`f
`P l<~JlOtl1CI)()t1
`1
`I
`resistance.":
`,
`1 II'!
`C 0Pl{ ogre.
`0
`Furthermore,
`Lau ct all';,I:1 recently reported that clopi-
`is less ,'ITenive
`pl:tl<jl(~1:'lggl'C!!;alion
`dowel
`ill
`iJlhibiJ"illg
`when
`wu h ntorvastruiu, which
`cl):1d1T)iJli~I'<'I'\:d
`may
`of' clopidogrcl via c)'to-
`IlJhibil'
`tlw 1l1l;I:I!lnlic
`uct ivarion
`jA,'9 alrhollgh more recently a
`('.lI1'<)tnl~ P'150 (CYP)
`c.!opidogrcl--alOrvastalin
`interaction
`has
`been
`<]IIC5'
`'rhe~e
`racl~ and ollr
`intl,n:6{' 1'0 ,kVl~l(lp Hovd
`lioned,).()
`ami,thrombotic
`ageIJ16 PI'oU'lpll:d \I~ ('0 $~at'(~h f('JI'
`:t
`llt('J1't:
`'tlll.iplitld"t
`;1{!;Cnlwith
`grcolWl' P2Yq inhihi-
`atil':tt:liVI:!
`than
`and cl()pid()J~reL
`Inr), activity
`\'Jut of tidopidinc,
`CS-747
`(2"acetoxy,-5"'(CI.··c)'dopropylcarbonyl
`..2..
`flu()roben~)' 1)..4,5,6,'1"1','\'1'\1
`hyd 1'<.1thil,:nll
`[3,2-<:,jpyri.( Ii l'J<.:)
`l) i, a lh, ")1(.1)1yt'idyl pl'c.1dl'ug
`Ihu' I' 11'll,t;iholi'l,(:d
`(F,ip;,
`
`C$ ..l41
`FiOllro 1 Chomic(,1 t;li'ucW'-OGof CS,.'j'l'I and ilfo activo motabo'
`Il!J!J?7.4!H-'1 ;il:ll/.7, 1'1-1:ll:l1Tl I:; (I lrlixI\Jre of fc.)\11 i~C)I1'l1,!I~, H-
`liW,
`!)D:t.:!4I:) Q ll'IixlulD of {rI, S). (Jfld {S, RJ-itlOrnC(::; (a (;ornpo'K:nl of
`1'l-'13H7?71
`
`rc,
`
`moraholi
`plarclcr-inhihirory
`active
`the
`in vivo to
`antagonistic
`P2Yl?
`receptor
`1), with
`(Fig,
`R-13g727
`activity, Our previous reports showed that CS·-747
`is ,HI
`effective
`orally active platelet
`am~regati()n
`inhibitor
`with
`high
`J<.lnl~duration
`pcm:IKY,
`fa~(' OIl,~I;i',
`;Ind
`;Ktic.111
`(If
`:->luclies?:1 ;),~ and in ,I clinical
`Sll1dy/1
`borh
`in preclinical
`In this article, we will SUI\1I\1Hizt!
`the evidence
`lor
`the
`potential
`clinical
`usc ofCS-7'17,
`a novel P2Y12 inhibitor
`nuriplarclcr
`agent,
`In
`the
`treatment
`of
`thrombotic
`disorders.
`
`PRECLINICAL PHARMACOLOGY
`
`Inhibitory Effects on Platelet Aggregation
`
`ANTIAGGR!!GA TORY ACTION
`pOlEN!
`is a
`CS-,74'1
`ro clopidogrcl
`and riclopidinc,
`Similar
`a~say~
`and is
`inactive
`in platelet
`aggrep;ation
`prodmg
`added
`in vitro, When
`to
`administered
`orally
`when
`experimental
`animals,
`CS-747
`h:l~ xliown
`}WWt'V\:).',
`or platele! ag)';n:gfl-
`dose-rclurcd
`and pOI\~n\' inhibition
`is appJ'oxim:II<;ly 10- and 1OO-J()ld more potent
`rion rhut
`I'han that
`of d()r,d()g('t~l
`riclopidine,
`respectively,
`,tnd
`ex vivo anriplarclcr
`Previous
`rt~p()rts~,1 comparinj,
`the
`pnt\~l1t:)' of CS-'l'17 with
`riclopidinc
`and clopidogrcl
`(OJ to 3 mg/kg,j'J))
`mrs showed that
`(:5,·747
`inhi])il(;d
`ADP"ind\l(:ed
`platelet
`agg-n:.g;\tioll
`in
`dO:->l!-l'd:tl~!d
`by SO%
`manner with a dose
`1,1,;11' 1'(:.<.IIIC(:'<.1rile I'(:sponse
`(Ej)~I)) o{ 1,2 mt~/kr~and thar
`clopidogrcl
`and ticlopi-
`activity, with EDso
`dine showed
`less potent
`anriplarclcr
`0/',0,) and :-:-,300 IT,p.;lkg
`(/),1),),
`values
`of 16 mg/kg
`respectively
`(Table 1), The potent
`antiplat(,l(:1
`:((,~Iivily
`of CS'·,(4'1 was ah<.l ",<.l,,(il'll'll,:d in
`study,
`clinical
`:1
`summarized
`later.
`
`ill
`
`!(
`
`RAPID ONSET AND LONG DURATION OF ACTION
`of platekI' aggregation wi,th lidopidine
`] nhibition
`,ttld
`:,1 1'<.15 da)'~/I
`i~maintailll'd
`Ihis
`clopidogrcl
`OV(:r
`'Ind
`lIr acti(1) by both ag\!"I~ i~:illl"ICliw
`in
`long dlll'ati.on
`time 1'0 peak pl:\l'clci
`('.linl<:al sil'\1rttion~,
`I-Iowevel',
`Ihtl
`r,low2';,?,(,; CS-7117 shows
`inhihition is rehllivoiy
`not on I)'
`activity hilt also a more rapid
`long-hs('inl~;
`:ll1l'iphtdct
`onset of action ('han c1opidogrel docs in rat antiplntdCl
`The time COIII,'~e ~I'lldy on the antiaggn:p;atory
`studies,
`df(;(;('~ aft'er adrninim:nion
`of CS"'14'1 (1 to 10 1llg/kg,
`lInd dopidogrd
`(10 to 100 mg/kg,
`/" ()_) "how"
`jJ,rJ.)
`th}ll
`than
`!l()% inhibition
`wa::
`()b~crvcd
`in
`l'nol'C
`CS-747-trc,llcd
`(10 mg/kg)
`1'<11', 30 rninllte,;
`an'cr
`the
`dOoing, Wh':I'l:a~, at
`lhc ~:m:I(: limc point,
`dopidog)'(:.l
`exhibil'e<1
`rnillilt'ial
`inhibil'i(HI
`<~Vl;t'i al
`\'he
`hig-Iw~t
`do~c Hs,:d (Fii~' 2), sllmr,cst'ing
`c;\r]iel' on:,et' oj'
`:tcl'i01\ oj'
`CS-747
`compared wit'h dopidogreL
`The mcchani:lln
`
`:01, This page 83 of 99 was completed at 24,12,2010 14:14:07
`Duration: 24,12,2010 13:40:37 - 24,12,201014:21
`Received at the EPO on Dec 24, 2010 14:21 :01, Page 83 of 99
`
`
`IPR2015-01492
`Panacea Biotec Ltd.
`
`
`
`
`Ex. 1044, p. 2 of 11
`
`

`

`24/12 2010 FRI 13:15
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`~084/099
`
`186
`
`S"MINARS IN THROMBOSIS AND I'I"MOS11I$ISIVOWME
`
`of Antiplat(.IM.
`"lIble 1 Comp,lr;son
`Clopidogrcl.
`and Ticlopidinc
`
`----------------------------
`::n. NI)MBEH 2 2(105
`
`Antithl'ombotic::,
`
`and Antihamostatlc
`
`Effects
`
`of CS·747.
`
`Agorlt
`-"
`CS-747
`Cloplucqrel
`'i"i<'llopi(illll"
`
`AV·Shunt
`(ED"ollvl
`_;__.::;:::='-- __
`0,6f3
`6,2
`>:lO()
`
`A9greglltion
`Bleeding
`_;_-"'==- __ ,~..'",_,._(B_T_,L
`(EOo"I\",,1
`1,2
`0.50
`Hi
`4.(j
`>:3(lO
`1:10
`
`R!ltio
`J§pl<OI\v/BT_o"')__
`1.4
`1.:3
`> ~!.:j
`
`1..11
`:Ui
`.,. 2,3
`
`___'_(E_D...:!.",·Ohc:;Cl;;_;,.Cl;:_/_B_r=,1
`
`by CS"74'l may rellccr
`this mccliauism.
`
`in.\,v'::l'~ibk
`
`1"2Yl~ bl()(~k:tdl~ vi:\
`
`ilOlll SIIIJHj,lClli (ll al"
`Dal'l
`I\V shul1l
`th(,
`IN,,()I anrl
`In pl{lt~l(lt
`to 1M'; II hours before' eV~".lllliQn.
`ArJ0"'H~wore orally administered
`flflWf.lllfl\lon
`(1(I(.lil1()!lli()/\find Ihl()l\\bu~;
`ill willeh II),) (lgOI)I" 1I\llIl)iwd pilltelol
`Ih'roIllIJO!li, ",oil", I, 11>,·,LD"fl vill"(-)}I IIl~~)/k9) .uo (lo,;",;
`[oll't1i'ilio(j by bO'ro.
`l3T;> v(liueG ("I1(J/k\J) (11'0dosos (II whkh Ihe ~ql,)')15 (Iollbl/)
`lime (tn).
`Iht3 l)a;,(,!liIW 1)I(:~(;~r.lin~l
`the rapid onset or CS··74T~ effect
`remains
`underlying
`1'0 be
`elucidated
`but
`rnig;ht
`reflect
`either more
`rapid
`aIJ"'I'jlt'i(.ltl
`<.),' ":Ipid llll;taboli:.;m 1'0 it~ a('.tiVl~md;lhnlit(,
`ill vivo,
`compared with c1opid()l~r()l. CS-747
`showed
`clfccrs at 4- hours post dose, with
`maximal antiplatclct
`anriplatclct
`cfiicacy
`as
`Ion)!;
`lasting
`as
`clopidogrcl
`inhibitory
`(Fi.g, 2), At 96 hours
`post dose,
`the platelet
`eH(.',ct's of CS','/4'/
`largely disuppeured. This prolougecl
`o( pl:l(dl~1 :1!:\,gl'l~glJ.li()l} by CS-747 and clopi-
`inhihilioJl
`cloy-no] S(:l!mS to be
`comparable
`to the
`spall
`of
`life
`."
`.
`",2H
`.
`.
`circulating
`platelets
`tn the
`rar.:":"
`Recently,
`It has
`been proposed that
`the action of rhicnopyridyl
`prodrugs
`reflects
`the
`forrnurion
`of a disulfide
`bl'idg<:.
`between
`rhe
`reactive
`..hiol
`g!'()UP oj'
`('il<.: <\\:I'iw ll)(:t·a])olit·(,
`and
`of' (ill: pbldet
`I'lY1;). ADP
`(:Y~I'('.iJl'"
`I'~~i<.hw($)
`recept()rs.:",,~11) Therefore,
`this
`long duration
`of action
`
`and Antihemostatic Effects
`Antithrombotic
`The
`IWO most widely
`used oral
`nntlplarclct
`:l~~ents,
`p,'od",(,,: ~igllifi(,':1111din;":lllwn,~-
`nspirin and d')pid')g,'(d,
`(it~, but
`('lIl,:i.1' 1'(~lll.liv(: w(,;\k ll!l(ilhl'ombnlic
`l~n(!d,; aI",!
`considered to be a major
`The potent
`litl1it,lIi()n,~\l
`anti-
`aggrcgatory activity of CS ..7'17 provides
`improved an-
`rirhrombotic
`effect over existing nnriplarclcr
`;IW'·lJI~,In 1I
`(AV) shunt
`thrf.lr)'lhf.l~i~ rnodd,:n,:n oral
`rat arteriovenous
`:Idminist'l'ali(ll)
`of' CS-,/4';
`(0.1 1.<'>
`:3 mg/kg)
`4 hours
`hd(lt'(~';1':lI'Iin1-';:l
`]O-minlll.e
`circulation
`of'blood
`through
`or thrombus
`rhc A V shunt
`resulted
`in inhibition
`forma-
`an ED so or
`tion in a dose ..related manner,
`exhibiting
`
`(A) 60
`
`10
`o
`
`(8)
`
`GO -
`
`"-o~'" C()l1tr't)I
`___
`1 mglkg (p,o,)
`-(]-3
`-.-10
`
`72
`48
`41224
`Time after (iMino (IIr)
`
`96
`
`< ,
`
`\
`
`\
`
`lid,
`
`....
`
`*;
`,
`"'*
`"-0
`
`4
`
`i-Q-~-{)--------O
`"'n~. - ~,- .t.
`1\ 1t*
`."----
`...-
`-8
`'O~
`"*'
`--
`I
`2
`0,5 1
`J
`72
`46
`41224
`TilnO ..ft(>rdosing (tlr)
`lim!;! atter dosing (hr)
`illl"I'W wa,; 11'Will'L1rG(i~I O,G,
`Til)l(;) course oj sntiplatelet ettects of (A) C8-747 and (8) clopidojrel. Exvivo platelet ('09reg~lii(ln
`Figura:?
`4f:j, T~, iHH,1 m511(l(W; ilfl~!r ,I ~,;ill(ll~~ (Hill r.jo:;(:~oi (;)ilCh 'lfWfll. A(.)P ,1\ ~ G(lIl(:(~Il\ri'!ir.lI\of
`ll~,;I,~(lil~ IIw iHJ(ll1i~I, Hr.·!:;(JI\:;
`:3 11MWil!;
`1,7,,4,74,
`'p .::0.05,
`., p « 0.01 vornun control
`(vchicirH(();,ted (jrollpl by
`the moan (SEMI (1) .... 6).
`aro pr():;(I(lkd
`(1:1 Iho rnce» "I, ,ltandnrd error of
`\(,,~~t.(l:re)!)l ~;unid"IGhi /\, e\ ,,1,81,1 Pharl1ll1col 2000;1/.~l;'I443, H('printed by p,lImi~'~;i(ln,)
`tbe i)1.lnIWt\
`
`- -0 - CMtl'OI
`- '•.
`- 10 mg/kg (p.o.)
`-0- 30
`,.,..
`-100
`
`96
`
`:01. This page 84 of 99 was completed at 24.12.2010 14:14:30
`Duration: 24.12,2010 13:40:37 - 24.12.201014:21
`Received at the EPO on Dec 24, 2010 14:21 :01 , Page 84 of 99
`
`
`IPR2015-01492
`Panacea Biotec Ltd.
`
`
`
`
`Ex. 1044, p. 3 of 11
`
`

`

`24/12 2010 FRI 13:16
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`-----·------··--···-·--···-·-·-,···-··,.",,,."w.,,,,.,,"_.w_.~_,
`
`~085/099
`
`187
`
`1.1 AI.
`
`---------.-
`
`(A)
`
`(8)
`...-
`~ 60
`'-'.:l: 50
`t.f)
`'Cj) 40
`;:
`tn 30
`::::I
`~ 20
`o.E 10
`
`I-
`
`(C)
`
`o
`
`1
`0.1 0.3
`CS~747(mg/kg, p,o.)
`
`3
`
`o
`3
`1
`Clopidogret
`
`30
`10
`(mg/kg, p.o.)
`
`I'HAflMACOLOGY 01' CS-141fNIII":;t)
`..,__.._.._ _.._ _._.._.._ _._.._._.
`_
`!idnpidi Elf)(10 I'() 300 1))g/l<);,
`of (j,2 mg/kg, Ahhollgh
`1',0,) produced
`a statistically
`signifimnl
`inhibitioEl
`ol
`ED,o
`p..;rcatel' rlian
`the
`was
`thrombus
`formation,
`300 Iflg/kg
`(maximum inhibition
`of
`less than 110%),
`These
`results d~~;ll'l)'indicate
`(h;\! CS·-747 has more
`,",:livity
`(:I)lnj);\1.'cd with clopido-
`potent
`antirhromboric
`and riclopidinc. The rank order of the
`grcl
`:11"1(;1.1".1\1111-
`boric potencies
`<lmong these
`three aR.:nl:s is Ihl~ S:llll(, :l~
`dw !';Il)k order
`for ADP Olnti"p;g;-cgatory
`potencies,
`lit.lgg!:litillg that CS·-'!4'! exerts
`its in vivo unrirhromboric
`dl(:cl$ by ;ntcr!(;l'ing
`between ADP
`with the interaction
`to inhibition
`and AD1'
`1't!(:epr()I's Of) pl:Hd(~llj,leading
`oj"
`the plarelcr
`:l~~gmv.;:ll"ion component
`o( the thrombotic
`of- urreriul
`mass,
`Furrhc»
`evaluation
`in orhcr m()dd~
`thrombosis
`also has demonstrated
`potent
`an lilhl'(),-nbMic
`of CS·:14'1:'" Taken
`efficucy
`rogcrhcr
`these
`results
`indirak
`that
`the autirhromboric
`efficacy of CS-7'l7
`is
`'IPP"l)ximiltdy 10 and 100 times
`that of
`gn:atn
`than
`l'~~'p(~,:(ivdy,
`clopidogrel
`'lnd l;d()pidin(~,
`dTi;(\"~
`To
`determine
`p()~,ibh~
`'IT)tih':lTIl)~(ilti(:
`or CS··747,
`rat
`rail
`transccrion
`hleeding
`1:;1Il,,~:1~; wen:
`measured 4 hours after dosing, and die cfi~C1S ofCS-7<17
`WI":<; compared wid,
`those obtained with clopidogrcl
`and
`rng-/kg, p,o,)
`:1
`riclopidiuo.
`CS-74'/
`(0.3
`prolonged
`il)
`bleeding
`rimes
`in >l dose-reluu-d
`manner wirh
`dw d(1~t:.
`required
`to double
`bleeding
`ti1J)(~~, :1 B'l';~ V:.JIl(~, of
`0.50 mg/kg
`(Table
`1). Clopidogl'cl
`(.1 I() 10 nlg/kg,
`jJ.o,) and riclopidinc (30 to 300 mg/k),;,/"o.) also showed
`of bleeding times, with B'I2 values or 'fJi
`prolongation
`:111dno Il1g/kg
`(j),(),), 1'(:~pcctiy(:ly,The rank order oft-he
`anrihernostnric
`pnrt~ll'~;t:,
`amnllg
`tIH~~(~t-!IT'(:<::lg('M~is the
`as the order of the anriplatelet
`same
`and antirhrombotu:
`potencies,
`slIggcsting
`the antihcmosratic
`that
`effects
`CS-'/4'!
`arc (hie to its plarcler
`inhibitory activity,
`
`of'
`
`o
`
`100 300
`30
`10
`Ticlopidine (mg/kg, p.o.)
`1·:·11(lcH; of sin(ll" crat adminisuatio»
`of (AI C5:/117,
`Figur" 3
`(0)
`clopiclO(JI"OI,(Hid (C) li(;i(>pi<lin!)on II1(ombl.J~ [ormation in th~~AV
`in rats. 13100clcirculntiol' we,,;
`:;h\/rlt
`,ltml~1d II IlOur:; Hfl,,! (l!~1
`<j():~il)fJ of \1"1" il!J(-JIIH;. H~lwlt", ~Ie preseoted as the mean (.I: SEMI
`thrornbus w()iqhl
`:,0 I))illl/l():;
`(n·,·, G).• p «, 0.05,
`·~/J<O,Ol
`(II
`(From f;WJidachi A. ut (II. Br.J Phnnnncol
`V!:)!!;LJScontrol
`(0 1T1!.1/kq).
`znoo: 129: l/l4/1. Ikpi
`illlHd by P!~Il1Iissi()n.)
`
`of
`1). Oral administration
`O,()8 mg/kg (Fig, 3,
`'r;thle
`clopidogrcl
`(1 to 30 mg/kg') also deCl'(~;iSed t·hl'fllnbuij
`w(~igh(· ill a dlm~··rclatcd
`rnannerwith
`an est"im,lI"ed ED~{)
`
`Combined Effects of CS·747 with Aspirin
`Our data, as described
`in the pl'(~c,)diJ\g ~1)!~("i(Jn~of' !"Ilis
`that CS-7117 has more pOlCn!"
`article,
`clearly
`indicate
`and anrirhrombotic
`antiaggregatofY
`activities
`than ()dH~I'
`;tvailablc::rhicnopyridyl
`have, namely,
`currently
`prodrugs
`the most widely
`ridopidinc:
`alld
`clopidogrcl. Aspirin,
`lIs(~d an(.iplat"(~lc;("a);<::J1(",is a cyclooxygcnasc
`inhibitor,
`and
`its 'lIHi;lgg'-l~!',;<lOl')' d'f~~(:li~~p\,\~ifi(~againot
`thrornboxanc
`A2-mcdi,\l:cd
`platelet
`distinct
`agl~I'~W\li()n,
`:1 ruecluuustn
`from that of rhicnopyridyl
`prodnl!~,~_Clinic:llly,
`C<)IYI""
`bined treatment
`of aspirin
`plus dopidogrd
`Ius shown
`\·Jlica(:)'
`thrombotic
`'lddirivI:.
`ill preventing
`disordcrs,:\f,
`of C:S··'/4? included the study
`()f
`Th(~l'e!ill'e, evulunrion
`the effects of CS-7t17 in eOJlli)iTlali()l) with
`a~pir:in on
`platelet
`aggregatioll,
`thrombus
`formation,
`;llld bk(~diTlg
`times ill experimental
`animal models,
`In ex vivo I'M pluteler
`neither
`studies,
`aggregation
`CS-747 (0,(' and 1 rnglkg,/'''.)
`:ti(l!W (ll' aopirin (l() mg/
`kg, p,o,) alone showed any !;tatisticilily significllllt
`)nhibi-
`by collal?~l\
`finn
`1)1" I'at platdet
`ag).(J.'cgation induced
`
`:01. This page 85 of 99 was completed at 24.12.2010 14:14:59
`Duration: 24.12.2010 13:40:37 - 24.12.201014:21
`Received at the EPO on Dec 24, 2010 14:21 :01. Page 85 of 99
`
`
`IPR2015-01492
`Panacea Biotec Ltd.
`
`
`
`
`Ex. 1044, p. 4 of 11
`
`

`

`24/12
`
`2010 FRI 13:16
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`~086/099
`
`SEMINAIIS IN THROMBOSIS AND HEMOSlASISIVOLUME
`
`31. NUMBER 2
`
`2005
`
`*:¥
`
`D Control
`• Aspirin
`IlIJll] CS-747
`~ CS·747+Aspirin
`
`80
`
`60-r:
`40
`C) 20
`
`~~Q
`
`0
`
`~ ~
`
`1::1'1
`..:(
`
`188
`
`..
`
`0
`0.6
`1 mg/kg (p.o.)
`CS-747
`10
`10
`10 mg/kg (p.o.)
`Aspirin
`(Jf CS··l~/ and Qf;pirin Of! platelet <l~Jgr(;~JQlionin 1'<11:;whon adminitH(;[(:lIlllonc
`or in combination, Aoenw were ori11ly
`[ffHw;
`I"igura 4
`,lcil1linislered \0 rats 2110llfll before blood collection.
`l'l,llelol ~19(Jr':'!ylti(JnW<15induced by H) I'D/ml. colli.'O'~'L 11",!;\oIb ')1"1"
`\'Xr)(,~,;s(,"f ilS
`tI),~D\J/\n(!!lll-l:;l.
`moan
`.l: ~;I~M (n ......1)).•.•. p<:; 0.01 VI.!I,'U:;'.!(lnlf(lll)y
`
`0.6
`
`1
`
`2 h(lIl1"~,Ilk,. d<),~ing. 11(lw(,w.~I',CS-747 (0.6 and 1 mgl
`kg, 1'.(/.) when
`/'-0.)
`'~'J1nbin~~d wilL aspirin
`(10 mg/kg,
`showed marked inhibitiou
`of collagen-induced
`platelet
`'I).\F;rc!('l1:ion (Fig.
`rl),·11 indicating
`additive
`or synergistic
`cfTc:.~I:;of CS,,747 ';'ill1 aspirin, Combined
`a;ltiplatelct
`cffccrs Oil collagen-induced
`platelet
`aggl·l'g:ll·joll
`h:lv(,
`been d()(\1)n'.'/)I.~,d In in vitro ~1\J(.Ii(;s with human
`plate-
`'!'ill'
`/)\(~I,lholil"(~ Dr CS-74'!
`lets.
`(R-1.1R727,
`ilUIVl.:
`30 pl\ll)
`111cOlllblll,tl1(1)
`with :I~pi"in (300 pM)
`showed
`compared with
`nn additive
`antiplarclct
`activity
`either
`agent" alone.
`In contrast,
`additive
`effects were
`nut
`us tilt'. ag<.lIli~\
`obs(;l"ved when
`using ADP
`in rat ex vivo
`platelet ag).lfegatioll mllli(:~.;rl
`I.he in vitro results could
`To d('I'~~l'lI)i(l(:whether
`anrirhromboric
`cfficncy,
`ill vivo
`b(,
`a
`Il':\n~ht"l~d into
`and aspirin was
`examined
`combination
`of CS·747
`in a rat AV shunt" thrombosis
`after oral dosing
`2 hours
`model and on rat mil. transection
`bleeding t"i)l)(;~.Both
`CS"-'l4'1 (OJ
`and 0.6 I~lg/kg,
`ulone :lt1d :Ispil'in
`jl.O.)
`(lO mg/kg,
`/).{/.) ;\I(.)lll~ t\)()d'~I·:-lI.dy inhibited thrombus
`in file AV shun I', whereas
`aRent alone
`formarion
`neither
`showed
`:1l1)' si(~niiic<lnt prolongation
`of the tail rranscc
`S). Thl:
`rion
`blccdinjr
`times
`ar
`similar
`doses
`(Fig.
`/>.0.) with
`combination
`of CS··'747 (0.3 and 0.6 Il\g/kg',
`aspirin (10 rug/kg,
`j>,().) resulted ill gn.:at"n· aflti,ll"''>lilbo-
`tic d1~(~t$,~()mp:ll·,~dwilh either
`In conrrast,
`,Igt!rlt:ulonc.
`or CS-7'17 (0.3 and 0.6 t\1/!,/kg, /,.0.) with
`c()mhinalin\"!
`/,.0.) did not result
`in a statistically
`aspirin (1.0 mg/kg,
`prolongation
`of bkeding
`rimes, alt-hough a
`significant
`trend W,\~ ob~l::rVt:~d.'1'11(:,,:: /'(;Hlllt~ S\lgg<.:~tI"h:\I" :, combi-
`nuriou
`of CS-'/47 with :I~pi"in m~)' provide
`(1 gl't\;\I"CI'
`anrirhromboric
`eHCCI" than either agent "lone wirhour
`a
`concomitant
`increase in bleeding I"lmes.
`As dC5nib<.:d pr<.:vioudy, CS·· 747 dlOWS carlier
`d()pid()g!'<::1
`inhihil.ion
`c()rnp~lr't;d wilh
`()fl~(!t or plald,~1.
`'l'IHls, we fUfther
`compared I"ht! com-
`~l(teroral d()~il\g.
`bined dTcct ofCS ..74'1 plu~ aspjJ'in to that of dopidogrd
`phi/;
`"opil'in
`:111(:'.ll'ly 11111<.:POI Iii" :lrtt."·l"he dOhing.
`[1) I"hi~
`"I'
`
`induced by collagen
`agF;regal"ioll
`ex vivo platelet
`study
`(20 ~lt~/I11L) was measured
`30 mi nutcs
`alrcr dosing
`in
`/,,(1.) ulonc ()ill'
`rats (Fig. 6). Neither CS·,747 (3 mg/kg,
`l.r)..) alone ~how(:.d ,\Ily inili])ln),'y
`(:lO mg/kg,
`aspirin
`dli.:u:;
`:.lOIniTl\l(,~~nth,,· d()~illg. CS-747
`(6 mg/kg,
`/,.().)
`:;ll<)w(:d ~Iighl'anriplarcler
`aloft,;
`ctfccrs.
`In COl1ITa:;t:, CS-
`747 (3 and (j mg/k,:~,/,.0.) ill combination with :topirin
`
`(AI
`Oi
`
`60
`
`i:~ 1111.
`. i..
`
`J ~...............
`
`OCOtllrol
`.Allpirin
`~ CS-747
`!:] CS·74'r+Atl.pll'lll
`
`08·747
`AIIIII(III
`
`(I
`I)
`
`(I
`10
`
`0.3 0.6
`o
`0
`
`(l.3 (l.G '11(J/kO(p.o.)
`10 10 rnlJlkg (p.o.)
`
`(0)
`
`i.e
`
`OConlrol
`• ASI)irin
`~CS·747
`§!.'l CS-747+Asplrln
`
`0.3 1l.6 0.3 0.6 m(Jlkg Ip.o.)
`(I
`10 10 mg/kg (f)·o.)
`10
`A,;pitirl 0
`Q
`Q
`l'igu(I) 5 (A) Ellccts of C3··1~} and aspirin alone cmel in conlbi·
`nation on thrombus torrn;~ti()n in tile, AV (;1\\111\
`in ril(,;. A!l',"II~
`ildmilli:;l~ll(·!d
`I)ow:. bd()/(·!
`Wf,!le tlfillly
`I,) 1;11:; /.
`(;if(";ul'ilini"l
`Ihel shont. Re;,lIll:; arc presented
`an tho moan .1. SEM
`throuqh
`/J -:: 0.01 V{,'rSl.l~; C(1n(rol by (h~, 1)'.ll"In(,!ll t<,,~;,
`• f.l':: 0.0':; .••
`·6),
`(Il'
`<)nd u!;pirin
`(1.1) Eff~~cI!;of CS,/rll
`"I)«l.()"t
`by Iht·) Tuhly
`ltd.
`~I()ne and in combil1lHion on wil
`\wn~eclioll
`lirn("'; ill
`blt!(e(lil1(l
`rat):;. AH(~n1.~W(~l(~ ()lallV rJdrnilHstHI
`(.)1.1 1(.> rilts /. l1our·~.;tXJfOI'B (;"liI
`i"l,l:illll;, aft, PfO;,(:nl(;d
`Irl(';~:lI1,I. SCM (II
`lI"i.)l)S(lClion.
`:I;) thfi
`(3)
`There ~[l' no slllt;,;Ii("lt dillef('n(:~!s ,ll ~I"IYp()if1~cr.lmpi",,,t w.~h
`(;OnlfOl (Ihn Dunnett lOra).
`
`:01. This page 86 of 99 was completed at 24.12.2010 14:15:27
`Duration: 24.12.2010 13:40:37 - 24.12.201014:21
`Received at the EPO on Dec 24, 2010 14:21 :01. Page 86 of 99
`
`
`IPR2015-01492
`Panacea Biotec Ltd.
`
`
`
`
`Ex. 1044, p. 5 of 11
`
`

`

`24/12 2010 FRI 13:17
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`~087/099
`
`o (:Or\If(l1
`• Aspltl,\
`IZICS·747
`L\\l c5·747"
`
`A~,>lrin
`
`o C,,,,lwl
`• Aspirin
`I!:l CIc.pldO(Jrol
`1IiIl CIDpldDDrol+ Mpiril\
`
`(H)
`_ 100
`£ 60
`c:
`..g 60~,
`~ 'II)
`.£' 20
`o
`1(10 1.lglkU (P,o,)
`100
`()
`Clopldl}(trlH 0
`1Q
`'ngl~g (p,Q.)
`0
`Anplf!l\
`10
`(l
`Figuro 6 Combined effects of (AI CS··i47 or fB) clopidogrel witll
`;l.,pil'ill
`
`(l111)1;1I<:ll<:)I."'~Hl'f:lcWiil)n il1c.iI.ll)c:ll.ll)yGI,lIl;IWln ill r~t~. i\H<:lnl~;
`wOI'O orallv <"dl'ninir;tol'edto I"t:l
`:lO minutu,l
`bolero blood collcc
`tion Platelet <i(.JI)I'80ation was
`indllced by 20 I'n/ml.. collagen,
`• n-: o.w';,
`':1:SI'.M
`(/l: ......OJ.
`H():;ulls
`illf:l
`('lXPlf:!:;~HCJ iI~
`IIHjilfl
`•• p '::0.01 \<01',;",; control by tho Dun,.,ott U»;\.
`
`(IO mg/kg,
`pronounced
`showed
`/,,0,)
`inhibition
`()f
`collagen-induced
`ap"
`indicating
`aggrc.;gation,
`platelet
`d'f.i~,(;t~of CS·-
`p;ll'l;nt addi,iw or oY'Wrgistlc Cl)lnbined
`the dr(;n~o(
`'/4'/ with
`:\~pirin, W(~ j',.,,'th<;)'
`c;v:\ll.l"t<~d
`('.1()pidogl'(~i (10() lng/kg,
`jU).) plus
`:\spil'in (10 lng/kg,
`!,.(i.) under
`the S;lI11e conditions
`and ('c)llne! only minimal,
`although statistically significant,
`inhibition. Taken
`to-
`the observed potent combined efficacy and early
`gether,
`of Hrl'i.I.JI)clf C5 ...'/47 plus aspirin
`11101)'huvc clinical
`onset
`relevance.
`
`Mechanisms of Antiplatelet Action
`
`ACflVE METABOllT!::
`Similar
`1:0 clopidogrel and riclopidine, CS-747 is innc-
`assays when
`rive in platelet
`aggregation
`added in vitro
`but, as described earlier, shows potent
`anriplarclcr
`and
`aurirhromboric
`effccrs ill vivo alter oral. dosing. suggest·'
`the; pl'\'~('Il\'{' ()f an active metabolirc
`of CS- '147,
`ing
`J\.nlc)llr~ tht! hepatic metabolites o( CS-747, W\~illiti"lIy
`identified R-~n2(·1 as a metabolire ",ilh
`phll.elc~('-inhibi-
`tory ],ropcrticti,2l,n
`Based on the chemical
`structure of
`this active mctubolirc, which contains two chiral carbons
`possible.
`in
`it·~ ,tt'll(l'Ill'("
`'t(,)'\",is'>IlI('r~
`are
`1~.Hll'
`I 1owev C:! 1', ahhollgh
`studies
`have b(;..,,) p"l'li.l)'lIl\'e,l
`several
`with R-')C)224, structural analysis has shown it
`I.(J be a
`mixture of only two srcrcoisomcrs,
`(R, S)..isomer and
`(8, R)'''i~onl(:i', R..:n:ntly, we identified
`:tnd characterized
`,1~ th(~ <\c:!.iVt~ nWI::.\b()lil:~!of' CS-'/47, ~:()n('aill'"
`R- 1:18727
`jn!~ the
`full c:()mph~rl'lcnt of
`the
`i'i'l111' optic:\]
`isonwl'S.
`
`P"IMMACO~OOYOf'CS'747/Nllll~U
`
`1'.'1AI
`
`189
`
`studies
`AggJ'\Wttion
`rhar
`it has p"opel't'ie5
`R-99224.:)~
`
`shown
`have
`R"138'!27
`with
`a1i:dogou~ ro those described li)l'
`
`AGONIST SELECTIVITY
`To determine
`the selectivity of CS-7A7 and irs active
`mcrabolire
`for
`diffcrent·
`awmi:;t:;, washed
`platelet
`plnrelcrs were used \'0 eliminate
`fibrin
`fonnution
`till'
`is u${:d in
`pb"I);\,
`I·hal'
`Ih"()I)IJ,i"
`As
`J\:~lllt~ when
`"I, R-99224
`shown
`in Figul'('
`(0.03 10 1. f.lg;/ml .) inhihi\<:d
`by
`in virro washed
`human
`platelet
`inducl:d
`'Im~l'l:g:llion
`ADP, The inhibition was concentration
`related, demon-
`that: reduced response by S()'N,
`srrarinj,
`il concentration
`(Jeso) of O,ll ~lg/mL. R,·99224 did not
`:dJ(_'ci:ADp ..
`induced shape change even at rhe highest COllu'l1trmio)'l
`aggl'(~g:\t'i()n ili<ll!(~(~d hy {:nl1:1g"'l
`used.
`i)l:\I(~kl
`and
`low conccntrarions
`o( thrombin was ulso p:tl'li:llly
`in-
`hy the highest
`hibited
`C01Kt:t1tT,ltiOI\ of R-99224 used
`
`(A)-~80 ,.
`tc 60sIII 40
`
`1:71
`
`~
`I:fl 20
`rn
`<
`0
`
`(8)
`
`100
`~ 80 -
`t_
`c:
`0 60
`-;;;
`40·
`~~.20
`C)~ ()
`
`0)
`
`(C)
`_100
`
`~ 80-c
`0 60
`:tl
`III:? 40·
`....
`Cl 20s o
`
`0.03
`
`0,3
`0,01
`COllagen (~glml'
`
`-o- Control
`--
`(1.03 'Jo/mi
`-0-0.'
`
`-0-- Control
`-+- 0.03 Ilo/rn I
`-0-0.-1
`-+O,l
`-s- 1
`
`0,1
`0.Q3
`0.01
`Thrombin (wllt1ml)
`In vitro c·)[[c·)CI:;of n-HOn'i
`(O.O:l--l
`Figura'
`!((J/III!..) Oil plillul(~1
`<lg!.jl'eoo\iol1 induced by (N ADP, (B) collaqen, MId (C) thrombin in
`!)UI'rk'lI) pliJ(l·~IBt:.~.H(1~ull:) (oH('~f~XPIH~.~:)(~da:i
`Wi)~I)({d
`Ih(·:
`IrH~ilt\
`'I
`•p< O.Oli,
`"p '::0.01
`corm:;po"dil1()
`SEM (n .5-·,6).
`VW,lU:;
`by
`llll:' 1_)ljflnc~llV~~;l.(From S"Oid~,-,hi A,
`I~t ,.1, 131' J
`conlrc)i
`by p':!lIlli:;,~io".1
`PhilrmtlGol 2001 ;132:bO.
`fj')j)lilltwl
`
`:01. This page 87 of 99 was completed at 24.12.2010 14:15:53
`Duration: 24.12.2010 13:40:37 - 24.12.201014:21
`Received at the EPO on Dec 24, 2010 14:21 :01. Page 87 of 99
`
`
`IPR2015-01492
`Panacea Biotec Ltd.
`
`
`
`
`Ex. 1044, p. 6 of 11
`
`

`

`24/12
`
`2010 FRI 13:17
`
`FAX 01992561934
`
`~~~ EPO Munioh
`
`~088/099
`
`190
`
`SI:MINARS IN THROMBOSIS AND HEMOSTASISIVOlUME
`
`~1, NUMBER ~ 2005
`
`the
`
`(l 1.lg/mL), However,
`I~-
`~cliYilX of
`anriplareler
`m-
`thrombin-induced
`99224
`and
`against
`collagen-
`against
`compared
`with
`that
`wus minimal
`SpOrlS(;S
`In rat platelets,
`the inhibitory
`ADl'-indu(C(,d
`responses.
`profile or plnrelet
`ag~~!,,'gat"il)J)observed was similar
`to the
`:dh,,' oral dosing.
`ex vivo p[''''fil~ I,ll' C$-747
`Further-
`more,
`intravenous
`administrution
`nf R-99224 (0.1 t·,)
`:)
`of
`mg/kg)
`to rats
`resulted
`in d()~c-!'d:H~,d inhihi(·ioll
`AJ)P:
`induced
`platelet
`<l!mregation.
`'Fhesc pliarmacolo-
`giutl
`results
`support
`the contention
`that R-99224 is an
`active metabolite ofCS··''147 responsible for inhibition of
`pl;m.:kt
`;\ggr(;galJ.e.lJ), We also note
`of
`that
`the inhibition
`by R..99224 persisted
`in vitro
`1':1\ pla\~'.h:1 aggrcg:ni.on
`;\(1t11' wr",hing tl\(: pl:\!·d(:t~ lip to rb)'~~ctimes to eliminate
`free R-9'J224 from rhe sysl(:n\. Similarly,
`inliibition
`of(;x
`aggree;ario!1 by CS-747
`(1 mg/kg, JUl.)
`vivo rat platelet
`was not diminished
`ann
`the platelets were washed three
`times, Sl1I9~estinl~ that
`the ultimate
`anriplatcler
`actions o(
`CS···'14·/
`and H,·992:?4
`arc similarly
`irreversible.
`These
`results arc consistent with the 10111-\ duration
`of action of
`CS-747 :I~ d(~,;rl'ib(,d curlier.
`
`P2Y1l BECEPTOR SELECTIVITY
`ro several
`Stimulation
`of platelets wirh ADP leads
`physiological.
`n·.~p()nses,
`iJ1l.:1mlinl~shape
`change,
`almre-
`or granule
`g:\1iOII, and secretion
`contents.
`These plarclcr
`l'('.~p(>ll~(:;; a)'<~.\'.ol1;;idt;)'(~d to be mediated
`by at
`leaw two
`distinct
`1'1I1'illt:l'gic (P2)
`1'(!(~epl·OI'';:J>2Yj nnd
`J>2Yj/..:1'1
`We examined
`the effects of R-')9224
`on rhe binding
`oj'
`CJ 1]-2-mcrhylthio-ADP
`(11I 1I-2-McS-ADP),
`a st:;blc
`liRall(l for both the P2Y I and P2Y l2 ADP receptors,·!()·,11
`to washed
`human
`plarclcrs to determine
`receptor spcci ..
`ficity. Trcarmcnt
`1(.,99224
`(0.1
`100 ~IM)
`with
`to
`I)f [:lUll·
`1'J'<)(hn:(:d a cnnccutratiou-rclatcd
`inhibirion
`
`tl_'
`
`Md)-·A.DP
`:( pl:JI~::,(l
`rc,\chillg
`binding, with inhibition
`l.lg/m1.,) H.··9922'L It should
`:3 pM.
`at
`Iw llnled,
`(1.4
`by 1<.,,·99224was subrnax-
`however,
`fh:ll: rliis inhibition
`(84% or C()[iI",'()l) <;V';ll at
`imul
`the highcsr
`concentration
`inhibited n r]-2-M"S-AIW
`used (100 ~lM). In ex vivo (,)1p(~!'inH:nl.$, CS-'14';
`also
`partially
`bindillg
`characterize
`To further
`rat platelets.
`washed
`the hindill!!;
`properties
`of H-99224, we used 0.3 pM ARL-(,(,O%,
`a
`and 300 ~1M.AJPSPS,
`s(,kCfiv~: P2YI~ :1I'tag()lJist,·u,~:I
`1.>2)\
`:\
`selcc(ive.'
`all1"ag()lli~t.4;1"H The
`couccnrrarions
`inhibition
`employed
`ShO'Wl~d maximum :11.:J,i\:vahk
`of
`1.:1Jn-2-McS-ADP
`binding.
`As
`shown
`in
`Figure.:
`8,
`10 ~1M.(/1.6 ~lr~/mL) of R-9922<1 in combination
`with
`C:;lIm.l no additional
`of [\lll-2-
`A.RL"M09()
`inhibition
`Mt.:.S-AI)P
`binding,
`In contrast,
`H··99224
`(10 pM)
`in
`abolished e'II}·
`(:(jnlbill~l!i()n with A3P5PS
`compl(~lely
`2-MeS-ADj)
`binding.
`I.ikewis«, A HI ,-660')6 combined
`wirh A3PSJ>S
`'lbolished
`C~ll]-2-Md)-ADP
`bil)(ling,
`These
`results
`clearly
`indicate
`rhar R-9<J221.{ Ius inhibi-
`wry activity
`to rhat of AH!..-
`toward
`P2Y 12 similar
`66096,
`is ;\ selective P2Y\2
`suggesting
`rhat R,99224
`ADP receptor aurugcnisr.
`To li.ll,th~~[' d(!\"Cl'lnill<; wh<:!thel' H.-992:'.4 il\hibit~
`we invcsligfltl:!d
`(h.., d'I~\'.I~()J"
`P2Y,,~ Iuncrion,
`plarelcr
`on
`ADP-induccd
`intracellular
`,;ignali.ng
`R-99224
`c';
`cvt·.nrs,7.2 P2Y1 receptors
`arc linked
`to hctC!"odin:lcric
`(G,) that
`proteins
`stimulate
`phospholipase
`C,
`leading
`to
`(1r intruu-Ilulnr
`Ca2 I .;) However,
`mobiJil',:II·i()ll
`R-99224
`hnd no em:CIS on ADP-iIH.loc(,d
`Ca~ I
`tnohili'l.:lIio!)
`in
`suggesting
`no activity
`of R-SI9224 on
`human
`platelets,
`In contrast, R..99224 neutralized
`P2Y lAD]>
`receplOrs,
`(PC) E.·
`ADP-medialed
`inhibition
`of prostagl:llldin
`induced
`udcnylyl
`cyclase
`ucrivaiion
`ill human
`pl:lll~kt~
`9), whid\
`is J)1(,di;l(~:d by P2Y)2 AI)!'
`(Fig,
`I'(:r~pt(_'l'~,
`
`(A)
`
`(B)
`
`(J)
`
`100
`
`'"'5
`t!
`:0 _
`o..Y.l
`.iI!
`CJ
`<f~
`III 60
`Ole.
`~~
`~~ 40
`~E
`u:::.
`.[
`;:=
`
`())
`
`80
`
`20
`
`r----,
`NS
`,@.,
`
`"'*
`
`120
`
`100
`80
`
`60
`40
`
`ZU
`
`fI'I
`
`0
`R-99224
`ARL·B6096
`
`+
`
`+
`+
`
`...
`
`0
`R·99224
`ARL-G6096
`+
`+
`+
`A3P5PS
`'1-
`Figure 8 (AI In vitro erlect~ of fHl9224 (10 ~IMI combined with ABL·66W6 (0.3 IlM) on I'HI·2-M(:!S·ADI)
`!)lndill\110 W<lslwd Il\HT,,1I1
`('ombined wilh IH~9224 (10 I.lM) or AHL·6G096 (0,3 ~lMI on ('HI··2··MeS·-ADP billdil1D to
`platelets. (13)In vitro dfl:,ct of A:lPljl'S (:.l(l(lI\Ml
`w:d,ed
`hlHT\,lll platelets. Hesults am OXP{(·J(;f,(·ld as lilt> ]\)(<<)I\:l:- SLM (II zr., (j). •• 1)< 0.0·', {\J~;,Iwl ~;i9niJi(';.lnt by H\e Tukev \o~t.
`(Frorn
`SU(jid!l(;i

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

Connectivity issues with tsdrapi.uspto.gov. Try again now (HTTP Error 429: ).

Refresh this Document
Go to the Docket